Stress Sensitivity and Reward Responsivity in Depression

NCT02798094 | Completed

• 1 other identifier: PSYC-154-14
• Study Type: observational
• Target: 219
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this project is to learn more about the different ways in which people process information that is stressful and rewarding, and how abnormalities in these two processes are related to depression.

Conditions

Depressed

Outcome Measures

Primary Outcomes (1)

• Stress Sensitivity: Salivary Hormone and Stress Challenge Test (TSST)

  Participants are required to give a speech and an arithmetic test in front of a panel. Saliva samples are collected at 8 points throughout the test.

  2 hours after beginning of Time B Appointment

Secondary Outcomes (3)

• Mood and Anxiety Symptom Questionnaire (MASQ)

  Administered at first baseline appointment and covers past 2 weeks

• Reward Responsivity: Probabilistic Reward Task

  Administered at second baseline appointment

• Snaith Hamilton Pleasure Scale (SHAPS and SHAPS-C)

  Administered at first baseline appointment and covers past 2 weeks prior to interview

Study Arms (2)

Depressed Participants

No intervention

Healthy Control Participants

No intervention

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Community sample

You may qualify if:

• Outpatients aged 18-65
• Currently suffering from unipolar depression
• Fluency in English, sufficient to complete the interviews and self-report questionnaires

You may not qualify if:

• Clinical diagnosis of bipolar disorder, psychotic disorders, current alcohol/substance dependence, or significant medical comorbidity
• Treatment-resistant (defined as failing more than 3 trials of anti-depressant medication)
• History of neurological insult (e.g., concussion), neurological disease, seizure disorder
• Smokers
• Pregnant women
• Endocrine disorders
• High suicidal risk, defined by clinician judgement
• For Healthy Control Participants:
• Adults aged 18-65
• No history of Axis I disorders according to DSM-IV-TR criteria, as determined by the SCID
• No first-degree relatives diagnosed with bipolar disorder
• Fluency in English, sufficient to complete the interviews and self-report questionnaires
• History of neurological insult (e.g., concussion), neurological disease, seizure disorder
• Smokers
• Pregnant women

Sponsors & Collaborators

• Dr. Kate Harkness: lead
• University Health Network, Toronto: collaborator
• University of Calgary: collaborator
• Harvard University: collaborator
• McGill University: collaborator

Study Sites (1)

Queen's University

Kingston, Ontario, K7L 3N6, Canada

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Saliva is collected at eight points across the second session in 5mL vials. Saliva samples are assayed for neuroendocrine hormones (e.g., cortisol). Whole blood is collected in EDTA tubes at the first session. Whole blood is currently being banked. No assays are being conducted at this time.

MeSH Terms

Conditions

Consciousness Disorders

Condition Hierarchy (Ancestors)

Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Neurocognitive Disorders; Mental Disorders

Study Officials

• Kate Harkness, PhD

  Queens University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: May 13, 2016
• First Posted: June 14, 2016
• Study Start: July 1, 2015
• Primary Completion: December 31, 2018
• Study Completion: December 31, 2018
• Last Updated: August 28, 2019

Record last verified: 2019-08

Locations

CA (1)